NCT00728481 - The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Eosinophilic EsophagitisGastroesophageal Reflux DiseaseEEGERD

Interventions

DRUG

Esomeprazole

Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks

DRUG

Budesonide

Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose \[Splenda-registered trademark\]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)

Trial Locations (1)

55905

Mayo Clinic, Rochester